Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

Metastatic Colorectal Carcinoma Clinical Trial

Official title:

Randomized Controlled Phase II Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02738606
• Other study ID #: 2015-1133
• Secondary ID: NCI-2016-0074020
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 25, 2016
• Est. completion date: December 31, 2025

Study information

• Verified date: February 2024
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial studies how well liver surgery and chemotherapy compared to chemotherapy alone work in treating patients with colorectal cancer that has spread to the liver (liver metastases) that can be removed by surgery and that has spread to the lungs (lung metastases) that cannot be removed by surgery. Liver surgery removes a portion of the liver affected by the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Liver surgery and chemotherapy may work better than chemotherapy alone in treating patients with colorectal cancer which has spread to the liver and lungs.

Description:

PRIMARY OBJECTIVE:

I. To determine a survival benefit of liver resection in patients with resectable liver and unresectable low-volume pulmonary metastases from colorectal cancer.

SECONDARY OBJECTIVES:

I. To identify biomarkers in blood and resected liver specimens that correlate with survival, and development of extrahepatic and extrapulmonary metastases.

II. To assess patients' quality-of-life in each treatment arm with serial questionnaires.

OUTLINE: Patients are randomized to 1 of 2 groups.

GROUP I: Patients undergo hepatectomy and receive chemotherapy at the discretion of treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.

GROUP II: Patients receive chemotherapy at the discretion of the treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.

Patients are followed up every 3-6 months up to 3 years.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 29
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with synchronous or metachronous diagnosis of resectable liver metastases by computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen

• Patients requiring percutaneous or intraoperative ablation of liver metastases < 2 cm in size are eligible

• Patients who underwent prior liver resection or ablation for colorectal liver metastases are eligible

• Patients previously treated with systemic chemotherapy and/or biologic agents for colorectal cancer are eligible

• The primary tumor in the colon or rectum may be intact or resected

• Low-volume lung metastases are defined as solid pulmonary nodules < 2 cm with non-spiculated contours, no benign-appearing calcifications, and =< 14 in number, diagnosed by computed tomography of the chest or positron emission tomography (PET)

• Lung metastases will be unresectable due to anatomic location, distribution, or patients' comorbidities, as determined by review of imaging by a faculty member in the Department of Thoracic & Cardiovascular Surgery

• Patients must sign a study-specific consent form

• Patients will undergo CT imaging of the chest, abdomen, and pelvis to evaluate lung and liver metastases within 60 days of registration; for patients who cannot tolerate CT contrast or have hepatic steatosis that reduces the sensitivity of CT, MRI of the liver will be performed

Exclusion Criteria:

• Radiographic evidence of disease other than liver and lungs, with the exception of mediastinal lymph nodes < 2 cm and hepatoduodenal ligament lymphadenopathy, diagnosed by computed tomography, magnetic resonance imaging, or positron emission tomography

• Serum bilirubin >= 2 mg/dL

• Platelet count < 50,000/uL

• Eastern Cooperative Oncology Group (ECOG) performance status of 3-4

• Patient refusal to participate in randomization

• Pregnant women are excluded from this study

• Planned stereotactic body radiation therapy (SBRT) for the pulmonary metastases

Related Conditions & MeSH terms

• Carcinoma
• Colorectal Neoplasms
• Metastatic Colorectal Carcinoma
• Metastatic Malignant Neoplasm in the Liver
• Metastatic Malignant Neoplasm in the Lung
• Neoplasms
• Neoplasms, Second Primary
• Recurrent Colorectal Carcinoma
• Resectable Colorectal Carcinoma
• Stage IV Colorectal Cancer AJCC v7
• Stage IVA Colorectal Cancer AJCC v7
• Stage IVB Colorectal Cancer AJCC v7

Intervention

Drug:
• Chemotherapy

Other:
• Laboratory Biomarker Analysis
Correlative studies

Procedure:
• Metastasectomy
Undergo lung metastasectomy

Other:
• Quality-of-Life Assessment
Ancillary studies

Procedure:
• Therapeutic Conventional Surgery
Undergo hepatectomy

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	The primary analysis will be performed in an intention-to-treat data set. Stratified log-rank test adjusting for the study stratification factors will be used to compare overall survival between the two treatment arms. The hazards ratio of overall survival for the surgery arm compared to the non-surgery arm will be estimated by fitting Cox proportional hazards regression models, adjusting for the effects of covariates including stratification factors.	From the date of randomization to the date of death or the date of last follow-up, assessed up to 3 years
Secondary	Incidence of adverse events	Tabulated by frequency and percentages, by grade, and by their relations to surgical treatment.	Up to 3 years
Secondary	Extrahepatic and extrapulmonary metastases	The Kaplan-Meier method will be used to estimate time to extrahepatic and extrapulmonary metastases.	Up to 3 years
Secondary	Intrahepatic recurrence	The Kaplan-Meier method will be used to estimate time to intrahepatic recurrence among patients randomized to surgery.	Up to 3 years
Secondary	Biomarker levels in blood and resected liver specimens	Univariate and multivariate Cox proportional hazards models will be fitted to evaluate the association between biomarkers in blood and resected liver specimens and time to event outcomes, including overall survival development of extrahepatic and extrapulmonary metastases, and time to intrahepatic recurrence among patients randomized to surgery. Univariate and multivariate logistic regression will be used to assess the association between biomarkers and response to chemotherapy	Up to 3 years
Secondary	Scores of the Functional Assessment of Cancer Therapy - General 7 questionnaire	Summarized using descriptive statistics including mean, standard deviation, median, and range. Summation of item GP1, GP4, GP2, and GE6 (higher score indicates worse condition) and summation of GF5, GF3 and GF7 (higher score indicates better condition) will be calculated for each patient. Two sample t-tests will be used to compare scores of each item or summations between the two treatment arms.	Up to 3 years
Secondary	Patients who abandon treatment		Up to 3 years

External Links

•   MD Anderson Cancer Center